Glimepiride Voglibose Metformin hydrochloride

Product Description

Glimiford MV-1

Glimepiride 1 mg + Voglibose 0.2 mg + Metformin Hydrochloride (SR) 500 mg Tablets

Description:
Glimiford MV-1 is a triple combination antidiabetic tablet designed to provide comprehensive glycemic control in patients with Type 2 Diabetes Mellitus. It combines three powerful agents:

• Glimepiride (1 mg): Enhances insulin secretion from pancreatic -cells

• Metformin SR (500 mg): Reduces hepatic glucose output and increases insulin sensitivity

• Voglibose (0.2 mg): Slows carbohydrate absorption and controls postprandial blood sugar spikes

Key Benefits:

• Controls both fasting and postprandial blood glucose

• Improves insulin response and reduces glucose load

• Convenient once/twice daily dosing with improved adherence

• Lower risk of hypoglycemia compared to monotherapy

Indications:

• Type 2 Diabetes Mellitus (when diet, exercise, and dual therapy are not sufficient)

• Ideal for patients with high post-meal glucose levels

Comprehensive Diabetes Management

This combination tablet blends Glimepiride, Voglibose, and Metformin Hydrochloride to deliver a synergistic approach in lowering blood glucose levels. It works by increasing insulin secretion, reducing sugar absorption, and improving insulin sensitivity. This mechanism helps achieve better control and flexibility in diabetes therapy.


Reliable Quality and Distribution Across India

Manufactured and supplied by trusted pharmaceutical companies, this medication adheres to stringent standards for effectiveness and patient safety. With a 36-month shelf life, proper storage in a dry place further guarantees product stability. Available through certified distributors and suppliers across India, accessibility is ensured.